Market Overview

According to fortune business insights, the global endometrial cancer market size was valued at USD 2.66 billion in 2025. The market is projected to grow from USD 3.01 billion in 2026 to USD 7.90 billion by 2034, exhibiting a CAGR of 12.84% during the forecast period. North America dominated the endometrial cancer market with a market share of 46.61% in 2025.

The analysis shows that top companies are strengthening their product portfolios through label expansions, clinical trial readouts, and regulatory approvals. For instance, in January 2025, GSK plc received expanded European approval for JEMPERLI (dostarlimab) plus Chemotherapy for primary advanced or recurrent endometrial cancer. This trend indicates a strong shift toward adopting immunotherapy-based combinations in first-line treatment.

Major Players Profiled in the Market Report:• Merck & Co., Inc. (U.S.)• Eisai Co., Ltd.(Japan)• GSK plc (U.K.)• AstraZeneca PLC (U.K.)• Pfizer Inc. (U.S.)• Fresenius Kabi AG (Germany)• Hikma Pharmaceuticals PLC (U.K.)• Teva Pharmaceutical Industries Ltd. (Israel)• Accord Healthcare Limited (U.K.)• Bristol Myers Squibb Company (U.S.)

SegmentsHigher Treatment Value to Propel PD-1 Inhibitors Segment GrowthBased on drug class, the market is divided into PD-1 inhibitors, platinum compounds, taxanes, and others. The PD-1 inhibitors segment holds the largest market share, as drugs like pembrolizumab and dostarlimab play a central role in treating advanced and recurrent disease. Their dominance is supported by broader approvals, strong survival evidence, and higher treatment value compared with conventional chemotherapy.

Use as Standard of Care to Drive Chemotherapy Segment ExpansionBy therapy, the market is categorized into chemotherapy, immunotherapy, targeted therapy, and others. The chemotherapy segment is leading the market, as platinum-taxane regimens remain the treatment backbone for advanced and high-risk endometrial cancer. Even as new immunotherapies are approved, they are often used in combination with chemotherapy, keeping treatment volumes high.

For detailed market insights: https://www.fortunebusinessinsights.com/endometrial-cancer-market-117372

Drivers & RestraintsRising Incidence of Endometrial Cancer to Propel Market GrowthThe rapid increase in diagnosed patients, linked to aging populations, rising obesity rates, and better cancer detection, has raised the demand for innovative treatment options. As the patient base grows, it encourages investment in gynecologic oncology services and the adoption of newer, more effective treatment protocols, boosting market growth.

However, the high cost of advanced regimens, including immune checkpoint inhibitors and targeted therapies, may hamper market growth, as their adoption can be slower in cost-sensitive healthcare systems.

Regional InsightsHigh Disease Diagnosis and Faster Adoption of New Therapies Propel Market Growth in North AmericaNorth America holds the dominant endometrial cancer market share and is projected to experience strong growth during the forecast period. The region’s growth is attributed to high disease diagnosis rates, robust oncology infrastructure, and faster adoption of immunotherapy-based combinations, supported by broad access to biomarker testing and favorable reimbursement.

Europe is the second-largest market. The growth is attributed to expanding regulatory approvals, strong national cancer programs, and the wider use of guideline-based treatments, which are improving access to advanced therapies.

**Endometrial Cancer Market Future Growth:**The endometrial cancer market is undergoing a major transformation, moving from a one-size-fits-all approach toward precision oncology. Today's treatment landscape is increasingly defined by biomarker-guided strategies, with therapies tailored to specific patient subgroups such as dMMR/MSI-H, pMMR, and HER2-expressing tumors. This shift is fueled by the growing adoption of immuno-oncology agents, targeted therapies, and antibody-drug conjugates (ADCs) that offer improved survival outcomes in advanced and recurrent disease. While chemotherapy remains a foundational treatment, innovative combinations are becoming the new standard of care. North America and Europe lead this transition, but rising incidence and improving healthcare access are creating significant growth opportunities in the Asia-Pacific region.

Competitive LandscapeKey Players Focus on Biomarker-Based Treatment Development to Strengthen Market PositionsThe market features prominent players like Merck & Co., Inc., GSK plc, and Eisai Co., Ltd. These leading companies are accelerating growth through strategic initiatives such as expanding drug labels, advancing clinical trials for novel combinations, and focusing on biomarker-based development. Their proactive approach to delivering more personalized and effective treatments for defined patient populations continues to fuel the market’s momentum.

Key Industry Development• April 2026: BioNTech SE announced positive Phase 2 results for trastuzumab pamirtecan (BNT323/DB-1303) in patients with HER2-expressing advanced endometrial cancer.• April 2026: Utepreva LLC launched the Utepreva Endometrial Sampler, an FDA-cleared device designed to enhance tissue capture for early diagnostic evaluation.